Journal of Virus Eradication最新文献

{"title":"8.3 – 00088 Epitope-Driven Effector Functions of Broadly Neutralizing Antibodies Across Diverse HIV Isolates: Insights for Next-Generation Therapeutics","authors":"C. Li, M. Phelps, J.M. Brady, A.D. Nitido, V. Okonkwo, D. Lingwood, A.B. Balazs","doi":"10.1016/j.jve.2024.100438","DOIUrl":"10.1016/j.jve.2024.100438","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 30"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bypassing primary antiretroviral therapy centres in Sub-Saharan Africa: An integrative review of the theoretical and empirical literature","authors":"Maximillian Kolbe Domapielle ,&nbsp;Sadat Zakari Abugbila ,&nbsp;Marshall Kala","doi":"10.1016/j.jve.2024.100580","DOIUrl":"10.1016/j.jve.2024.100580","url":null,"abstract":"<div><div>The uptake of antiretroviral therapy (ART) is critical to meeting the global HIV treatment goal of 95-95-95 by 2025. Although a few Sub-Saharan African countries have already achieved this target, the prevalence of bypassing primary ART centres in many countries in the subregion has negative implications for ART uptake and use. This study used the access to health services framework to analyse the evidence and factors contributing to bypassing primary ART centres by individuals in the sub-region seeking HIV care and support. We found compelling evidence of the prevalence of ART clients bypassing their primary ART centres in search of specialised care in higher-tiered health facilities. Others use bypassing to conceal their HIV-positive status to avoid social stigma. We argue that introducing specialised and differentiated ART at the primary level of care can address this phenomenon. While we anticipate that this measure will satisfy clients' desire for specialised care, we recommend enhancing public awareness about the effectiveness of ART to reduce stigma towards ART clients. Legislation and strict enforcement of anti-HIV stigma laws, which outlaw and criminalise stigmatising people living with HIV (PLHIV), could potentially be an effective stigma-deterring measure. To complement this effort, PLHIV should be empowered to understand legislative instruments and steps to take when confidentiality and discriminatory issues arise. We recommend further research in Sub-Saharan Africa to investigate the relationship between bypassing primary ART centres and client adherence. The findings will help design appropriate strategies to increase ART uptake at primary ART centres.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100580"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"7.6 – 00052 The Tuberculosis Associated Microenvironment Reduces CD8+ TCell Control of HIV at the Site of the Coinfection","authors":"S. Cronin,&nbsp;A.P. Casanova,&nbsp;Z. Vahlas,&nbsp;E. Lee,&nbsp;K. Fisher,&nbsp;A. de Vries-Egan,&nbsp;M. Sharabas,&nbsp;A. Kelleher,&nbsp;C. Vérollet,&nbsp;L. Balboa,&nbsp;S. Palmer,&nbsp;G. Duette","doi":"10.1016/j.jve.2024.100435","DOIUrl":"10.1016/j.jve.2024.100435","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 28"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"7.4 – 00119 Anatomic distribution of HIV-infected clones in tissues after longterm antiretroviral therapy","authors":"F. Maldarelli,&nbsp;A. Glassey,&nbsp;T. Nguyen,&nbsp;R. Gorelick,&nbsp;L. Adams,&nbsp;M. Zipparo,&nbsp;A. Rahman,&nbsp;S. Hewitt,&nbsp;K. Lurain,&nbsp;R. Ramiswami,&nbsp;C.Y. Lau","doi":"10.1016/j.jve.2024.100433","DOIUrl":"10.1016/j.jve.2024.100433","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 27"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3.4 – 00150 Unbiased Genome-Wide CRISPR Screens in Primary Human CD4+ T Cells Identify Novel Proviral and Anti-viral HIV Host Factors","authors":"U. Rathore,&nbsp;E. Dugan,&nbsp;N.J. Krogan,&nbsp;A. Marson","doi":"10.1016/j.jve.2024.100409","DOIUrl":"10.1016/j.jve.2024.100409","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 11"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study","authors":"Amir M. Mohareb ,&nbsp;Patrick Miailhes ,&nbsp;Julie Bottero ,&nbsp;Caroline Lascoux-Combe ,&nbsp;Julie Chas ,&nbsp;Sarah Maylin ,&nbsp;Audrey Gabassi ,&nbsp;Hayette Rougier ,&nbsp;Emily P. Hyle ,&nbsp;Constance Delaugerre ,&nbsp;Karine Lacombe ,&nbsp;Anders Boyd","doi":"10.1016/j.jve.2024.100574","DOIUrl":"10.1016/j.jve.2024.100574","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Given advances in antiretroviral therapy (ART), some people with HIV are transitioned to non-tenofovir-containing ART; the implications for people with HIV-hepatitis B virus (HBV) are unknown. We characterized HBV-related outcomes in people with HIV-HBV coinfection while not taking tenofovir-containing ART.</div></div><div><h3>Methods</h3><div>We analyzed participants from the French HIV-HBV Cohort Study in three treatment groups: (1) continuous tenofovir; (2) discontinued tenofovir; (3) never initiated tenofovir. We examined virological and clinical characteristics during follow-up. We assessed determinants of HBV DNA &gt;2000 IU/mL and alanine aminotransferase (ALT) &gt;2x upper limit of normal separately while participants were off tenofovir using univariable logistic regression with generalized estimating equations.</div></div><div><h3>Results</h3><div>Among 192 participants, 161 (83.9 %) were on continuous tenofovir, 22 (11.5 %) discontinued tenofovir, and 9 (4.7 %) never initiated tenofovir during a median follow-up of 14.5 years (IQR = 10.5–14.8). The median proportion of within-participant visits with undetectable HBV DNA was 96.0 % (IQR = 75.0–100) in the continuous group, 100 % (IQR = 84.0–100) in the discontinued tenofovir group (while off tenofovir), and 100 % (IQR = 95.2–100) in the never initiated tenofovir group. Determinants of HBV DNA &gt;2000 IU/mL while people were off tenofovir were detectable HIV RNA (<em>p</em> = 0.041), lower CD4⁺ T-cell count (<em>p</em> = 0.027), HBeAg positive serology (<em>p</em> = 0.004) and positive hepatitis D serology (<em>p</em> = 0.001). ALT elevation was associated with positive hepatitis C antibody serology (<em>p</em> = 0.012).</div></div><div><h3>Conclusions</h3><div>This proof-of-concept study shows that selected people with HIV-HBV coinfection may not lose virologic control of HBV when off tenofovir. HBV virologic activity while off tenofovir may be more closely associated with uncontrolled HIV infection and positive HBeAg serology.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 4","pages":"Article 100574"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143105156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6.2 – 00049 Multivalent CAR T Cell Therapy Shows Superior Potency in Controlling HIV Escape and Replication in BLT Humanized Mice","authors":"F. Severi,&nbsp;D. Bercow,&nbsp;K. Stallings,&nbsp;A. Criswell,&nbsp;F. Pennino,&nbsp;R. Acosta,&nbsp;T. Yang,&nbsp;D. Claiborne","doi":"10.1016/j.jve.2024.100425","DOIUrl":"10.1016/j.jve.2024.100425","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 21"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3.1 – 00145 Exploring novel HIV Tat inhibitors","authors":"S.M. Jablonski,&nbsp;J.A. Jablonski,&nbsp;L. Shuang,&nbsp;L. Ling,&nbsp;A.T. McAuley,&nbsp;R. Ronald Jr,&nbsp;P. Espinoza-Gonzales,&nbsp;B. MacTavish,&nbsp;Q. Gibault,&nbsp;S. Zhang,&nbsp;T. Bannister,&nbsp;S.M. Schader,&nbsp;R. Ptak,&nbsp;V. Garcia,&nbsp;C. Augelli-Szafran,&nbsp;S.T. Valente","doi":"10.1016/j.jve.2024.100406","DOIUrl":"10.1016/j.jve.2024.100406","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 8-9"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"8.6 – 00097 Increased HIV-1 proviral reactivation and reservoir size in people with HIV on anticancer treatment","authors":"L. Perez-Blazquez,&nbsp;E. Valencia,&nbsp;L. Martin-Carbonero,&nbsp;E. Mateos,&nbsp;M. Coiras","doi":"10.1016/j.jve.2024.100441","DOIUrl":"10.1016/j.jve.2024.100441","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Pages 32-33"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PP3.6 – 00064 Novel synthesized protein kinase C modulators show enhanced HIV latency reversal properties and synergize with a BET bromodomain inhibitor","authors":"T.C. Chou,&nbsp;J.A. Moran,&nbsp;J. Zack,&nbsp;P. Wender,&nbsp;M.D. Marsden","doi":"10.1016/j.jve.2024.100487","DOIUrl":"10.1016/j.jve.2024.100487","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"10 ","pages":"Page 63"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}